glp-1 alcohol reduction Anti-Obesity Rx and and Substance Use Disorders GLP-1 receptor agonists show promise

The reported daily fluid intake decreased for patients on dulaglutide from a median (IQR) of 4500 [3625, 5000] mL to 3000 [2500, 3875] mL, while it remained constant with placebo treatment, from 4000 [4000, 5000] mL to 4000 [3500, 5000] mL

Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)

Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers

& Zhou, Z

FMU graduates often explain this to patients as the body's thermostat getting stuck, empowering them to see that the problem isn't willpower it's communication breakdown

The analysis of secondary CV outcomes showed that nonfatal stroke was also significantly lower in the dulaglutide group compared with placebo (2.7% vs 3.5%, P = .017), however, dulaglutide did not show any effects on all-cause mortality ( P = .067)